FDA Boosts the Progressive Supranuclear Palsy Rating Scale!

Mov Disord. 2024 Dec;39(12):2127-2129. doi: 10.1002/mds.30040.

Author

Cristina Sampaio^{1

2}

Affiliations

¹ CHDI Management, Inc. the company that manages the scientific activities of CHDI Foundation, Princeton, New Jersey, USA.
² Laboratorio de Farmacologia Clinica, Faculdade de Medicina de Lisboa (FMUL), Lisbon, Portugal.

PMID: 39699249
DOI: 10.1002/mds.30040

No abstract available

Publication types

Editorial